Inspire Medical Systems, Inc. (INSP)
USD 186.97
(-1.96%)
USD 186.97
(-1.96%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 624.79 Million USD | 53.19% |
| 2022 | 407.85 Million USD | 74.75% |
| 2021 | 233.39 Million USD | 102.28% |
| 2020 | 115.38 Million USD | 40.62% |
| 2019 | 82.05 Million USD | 62.18% |
| 2018 | 50.59 Million USD | 77.1% |
| 2017 | 28.56 Million USD | 73.9% |
| 2016 | 16.42 Million USD | 105.03% |
| 2015 | 8.01 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 164.01 Million USD | -14.8% |
| 2024 Q2 | 195.88 Million USD | 19.43% |
| 2024 Q3 | 203.19 Million USD | 3.73% |
| 2023 FY | 624.79 Million USD | 53.19% |
| 2023 Q3 | 153.3 Million USD | 1.46% |
| 2023 Q2 | 151.09 Million USD | 18.14% |
| 2023 Q1 | 127.89 Million USD | -7.25% |
| 2023 Q4 | 192.5 Million USD | 25.57% |
| 2022 Q4 | 137.9 Million USD | 26.3% |
| 2022 Q2 | 91.38 Million USD | 31.71% |
| 2022 Q1 | 69.38 Million USD | -11.5% |
| 2022 FY | 407.85 Million USD | 74.75% |
| 2022 Q3 | 109.18 Million USD | 19.48% |
| 2021 Q3 | 61.68 Million USD | 16.48% |
| 2021 FY | 233.39 Million USD | 102.28% |
| 2021 Q1 | 40.35 Million USD | -12.3% |
| 2021 Q2 | 52.95 Million USD | 31.24% |
| 2021 Q4 | 78.39 Million USD | 27.09% |
| 2020 FY | 115.38 Million USD | 40.62% |
| 2020 Q1 | 21.34 Million USD | -20.66% |
| 2020 Q2 | 12.18 Million USD | -42.93% |
| 2020 Q3 | 35.84 Million USD | 194.2% |
| 2020 Q4 | 46 Million USD | 28.37% |
| 2019 Q3 | 20.86 Million USD | 15.69% |
| 2019 FY | 82.05 Million USD | 62.18% |
| 2019 Q1 | 16.25 Million USD | -1.87% |
| 2019 Q4 | 26.9 Million USD | 28.97% |
| 2019 Q2 | 18.03 Million USD | 10.97% |
| 2018 Q1 | 10.04 Million USD | 0.85% |
| 2018 Q2 | 10.93 Million USD | 8.92% |
| 2018 Q3 | 13.05 Million USD | 19.35% |
| 2018 Q4 | 16.55 Million USD | 26.85% |
| 2018 FY | 50.59 Million USD | 77.1% |
| 2017 Q1 | 5.29 Million USD | 0.0% |
| 2017 FY | 28.56 Million USD | 73.9% |
| 2017 Q2 | 6.04 Million USD | 14.06% |
| 2017 Q3 | 7.27 Million USD | 20.34% |
| 2017 Q4 | 9.95 Million USD | 36.94% |
| 2016 FY | 16.42 Million USD | 105.03% |
| 2015 FY | 8.01 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Abbott Laboratories | 40.1 Billion USD | 98.442% |
| Allurion Technologies Inc. | 53.46 Million USD | -1068.569% |
| Artivion, Inc. | 354 Million USD | -76.495% |
| Avanos Medical, Inc. | 673.3 Million USD | 7.203% |
| Butterfly Network, Inc. | 65.9 Million USD | -848.102% |
| Butterfly Network, Inc. | 65.9 Million USD | -848.102% |
| Bio-Rad Laboratories, Inc. | 2.67 Billion USD | 76.61% |
| Boston Scientific Corporation | 14.24 Billion USD | 95.612% |
| Perspective Therapeutics, Inc. | 7.1 Million USD | -8695.031% |
| CONMED Corporation | 1.24 Billion USD | 49.652% |
| Edwards Lifesciences Corporation | 6 Billion USD | 89.595% |
| Paragon 28, Inc. | 216.38 Million USD | -188.739% |
| Glaukos Corporation | 314.71 Million USD | -98.531% |
| Globus Medical, Inc. | 1.56 Billion USD | 60.165% |
| Integer Holdings Corporation | 1.59 Billion USD | 60.869% |
| Medtronic plc | 32.36 Billion USD | 98.069% |
| Nevro Corp. | 425.17 Million USD | -46.951% |
| Owlet, Inc. | 54.01 Million USD | -1056.821% |
| Penumbra, Inc. | 1.05 Billion USD | 40.974% |
| Vicarious Surgical Inc. | - USD | -Infinity% |
| Smith & Nephew plc | 5.54 Billion USD | 88.74% |
| Sonendo, Inc. | 43.86 Million USD | -1324.368% |
| STERIS plc | 5.13 Billion USD | 87.841% |
| Stryker Corporation | 20.49 Billion USD | 96.952% |
| Vapotherm, Inc. | 68.66 Million USD | -809.871% |
| Zimmer Biomet Holdings, Inc. | 7.39 Billion USD | 91.55% |